<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538482</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-21224</org_study_id>
    <secondary_id>R01CA253219</secondary_id>
    <nct_id>NCT04538482</nct_id>
  </id_info>
  <brief_title>DASH INtervention to INvestigate the Gut</brief_title>
  <acronym>DINING</acronym>
  <official_title>Determining the structural-and Functional-level Effects of Diet-specific Interventions on the Gut-microbiota of a Diverse Sample of Southern United States Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigators will recruit a generally healthy sample of 112 black and white adults&#xD;
      from Birmingham, AL to participate in a 28-day randomized, controlled feeding study.&#xD;
      Participants will be randomized to receive either the DASH diet or a standard American diet.&#xD;
      All meals will be provided by the study. Fecal samples will be collected at multiple time&#xD;
      points before, during, and after the dietary intervention and will be analyzed using PCR to&#xD;
      amplify the V4 region of the 16S rRNA gene and to sequence bases using the MiSeq platform.&#xD;
      Sequenced data will then be analyzed using QIIME. The investigators hypothesize that&#xD;
      participants receiving the DASH diet will have a greater increase in alpha diversity and&#xD;
      greater changes in abundances of CRC-associated microbes than participants receiving the&#xD;
      standard American diet. The investigators will also evaluate functional-level markers&#xD;
      including bile acid and short chain fatty acid (SCFA) production and inflammatory markers. If&#xD;
      the investigator's hypothesis is supported, they expect to see reduced production of&#xD;
      secondary bile acids (e.g., deoxycholic acid), greater SCFA production (e.g, butyrate), and&#xD;
      reduction in gut and systemic inflammation (e.g, calprotectin, IL-6) among participants&#xD;
      receiving the DASH diet compared to the standard American diet. The investigator's findings&#xD;
      will provide preliminary evidence for the DASH diet as an approach for cultivating a&#xD;
      healthier gut microbiota across racially diverse populations. These findings can impact&#xD;
      clinical, translational, and population-level approaches for modification of the gut&#xD;
      microbiota to reduce risk of chronic diseases like CRC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in alpha diversity</measure>
    <time_frame>baseline - day 28</time_frame>
    <description>The investigators will assess the difference in alpha diversity determined by analyzing fecal samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in alpha diversity</measure>
    <time_frame>day 28 - day 42</time_frame>
    <description>The investigators will assess the difference in alpha diversity determined by analyzing fecal samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diet specific changes in secondary bile acids</measure>
    <time_frame>baseline - day 28</time_frame>
    <description>The investigators will calculate changes in cholic acid in milligrams</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diet specific changes in secondary bile acids</measure>
    <time_frame>day 28 - day 42</time_frame>
    <description>The investigators will calculate changes in cholic acid in milligrams</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diet-specific changes in inflammatory marker</measure>
    <time_frame>baseline - day 28</time_frame>
    <description>The investigators will calculate changes in interleukin-6 in pg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diet-specific changes in inflammatory marker</measure>
    <time_frame>day 28 - day 42</time_frame>
    <description>The investigators will calculate changes in interleukin-6 in pg/L</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Microbiota</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>DASH Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard American diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DASH Diet</intervention_name>
    <description>Participant will receive foods following the DASH dietary pattern for 28 days.</description>
    <arm_group_label>DASH Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>standard American diet</intervention_name>
    <description>Participants will receive foods following the standard American diet for 28 days.</description>
    <arm_group_label>standard American diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  black or white race&#xD;
&#xD;
          -  non-Hispanic ethnicity&#xD;
&#xD;
          -  age 19-65 years&#xD;
&#xD;
          -  able to travel to the UAB Bionutrition Unit daily to retrieve meals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  gastrointestinal (GI) conditions i.e., irritable bowel, diverticulitis, peptic ulcers,&#xD;
             Crohn's, GI cancers, and adenatomous polyps&#xD;
&#xD;
          -  antibiotic or probiotic use in the previous 90 days&#xD;
&#xD;
          -  smoking/tobacco use&#xD;
&#xD;
          -  heavy alcohol consumption&#xD;
&#xD;
          -  major medical conditions (e.g., renal disease, diabetes, cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiffany L Carson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darci R Miller, MPH</last_name>
    <phone>813-745-0285</phone>
    <email>Darci.Miller@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany L Carson, PhD</last_name>
    <phone>813-745-4944</phone>
    <email>Tiffany.Carson@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiffany Carson, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tiffany Carson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

